Cocrystal Pharma (NASDAQ:COCP) Trading Down 5.6% – Should You Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP) shares fell 5.6% during trading on Monday . The stock traded as low as $1.17 and last traded at $1.17. 23,073 shares changed hands during trading, a decline of 59% from the average daily volume of 56,429 shares. The stock had previously closed at $1.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Cocrystal Pharma Stock Up 0.4%

The business’s fifty day moving average price is $1.05 and its 200 day moving average price is $1.13. The firm has a market capitalization of $22.05 million, a PE ratio of -1.51 and a beta of 1.48.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts anticipate that Cocrystal Pharma, Inc. will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Cocrystal Pharma stock. T3 Companies LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.